Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MARINUS PHARMACEUTICALS, INC.
Report date February 07, 2025 · Filed February 11, 2025
Section 16 reporting ended · disclosed 2025-02-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-07 · Disposition to issuer · Disposed 17,303 · Balance 62,470 F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Row 2 · 2025-02-11 · Disposition to issuer · Disposed 62,470 · Balance 0 F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F2: Represents 62,470 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2034-06-18 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-11 · Disposition to issuer · Disposed 57,300 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.74 · Expires 2034-01-18 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-11 · Disposition to issuer · Disposed 114,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2033-01-26 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-11 · Disposition to issuer · Disposed 126,585 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2032-02-04 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-11 · Disposition to issuer · Disposed 74,475 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.99 · Expires 2031-04-12 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-11 · Disposition to issuer · Disposed 220,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash.
F2: Represents 62,470 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Neuronetics, Inc.
Report date March 19, 2026 · Filed May 21, 2026 · Amendment
Section 16 reporting ended · disclosed 2026-05-21. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 836,643 |
Reported balance
After 2026-03-19 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-19 · Sale · Disposed 8,569 · Balance 836,643 F1: The Form 4 filed on March 24, 2026 inadvertently reported the disposition of 16,431 shares of common stock in connection with non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a performance restricted stock unit award. However, the correct amount is 8,569 shares of common stock. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.48 to $1.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The Form 4 filed on March 24, 2026 inadvertently reported the disposition of 16,431 shares of common stock in connection with non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a performance restricted stock unit award. However, the correct amount is 8,569 shares of common stock.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.48 to $1.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 24, 2026 21:52 UTC | Neuronetics, Inc. STIM · Entity 6248 | SaleCommon Stock | 16,431 | $1.34 | $22,017.54 |
DisclosureSEC source: 0001193125-26-122298 · ownership.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,781 F1 · shares: The sales reported in this Form 4 were non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a performance restricted stock unit award. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.48 to $1.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 19, 2026 Filed May 21, 2026 20:05 UTC Amendment | Neuronetics, Inc. STIM · Entity 6248 | SaleCommon Stock | 8,569 | $1.34 | $11,482.46 |
DisclosureSEC source: 0001856059-26-000002 · ownership.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · Former EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 836,643 F1 · shares: The Form 4 filed on March 24, 2026 inadvertently reported the disposition of 16,431 shares of common stock in connection with non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a performance restricted stock unit award. However, the correct amount is 8,569 shares of common stock. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.48 to $1.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:33 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-114111 · ownership.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 845,212 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in three equal annual installments beginning on March 17, 2027, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:30 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-071774 · ownership.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 820,212 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in three equal annual installments beginning on February 23, 2027, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 22:05 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 170,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-338392 · ownership.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,212 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (i) June 30, 2027 and (ii) the termination of Mr. Pfanstiel's employment from the Issuer without cause. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 15, 2025 Filed Jul 15, 2025 21:00 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-095914 · ownership.xml · nonDerivative · entry 2 Pfanstiel Steven · CIK 0001856059 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 F3 · shares: Represents a RSU award that vests in three equal annual installments beginning on July 15, 2027, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 15, 2025 Filed Jul 15, 2025 21:00 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-095914 · ownership.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in three equal annual installments beginning on July 15, 2026, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:13 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $13.99 | $0.00 |
DisclosureSEC source: 0001104659-25-011241 · tm255946-4_4seq1.xml · derivative · entry 7 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 220,000 shares Expires 2031-04-12 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:13 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 74,475 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001104659-25-011241 · tm255946-4_4seq1.xml · derivative · entry 6 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,475 shares Expires 2032-02-04 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:13 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 126,585 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001104659-25-011241 · tm255946-4_4seq1.xml · derivative · entry 5 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 126,585 shares Expires 2033-01-26 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:13 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 114,600 | $0.00 Strike: $9.74 | $0.00 |
DisclosureSEC source: 0001104659-25-011241 · tm255946-4_4seq1.xml · derivative · entry 4 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 114,600 shares Expires 2034-01-18 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:13 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 57,300 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001104659-25-011241 · tm255946-4_4seq1.xml · derivative · entry 3 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,300 shares Expires 2034-06-18 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:13 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerCommon Stock | 62,470 | $0.55 | $34,358.50 |
DisclosureSEC source: 0001104659-25-011241 · tm255946-4_4seq1.xml · nonDerivative · entry 2 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F2 · shares: Represents 62,470 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. F1 · price: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 09:13 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerCommon Stock | 17,303 | $0.55 | $9,516.65 |
DisclosureSEC source: 0001104659-25-011241 · tm255946-4_4seq1.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,470 F1 · kind: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F1 · price: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 16:05 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | SaleCommon Stock | 4,657 | $1.13 | $5,262.41 |
DisclosureSEC source: 0001415889-24-020898 · form4-08072024_040810.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,773 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.16, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 16:21 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 57,300 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001415889-24-017629 · form4-06202024_080659.xml · derivative · entry 2 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,300 Underlying: Common Stock · 57,300 shares Expires 2034-06-18 F2 · derivative.exercise_date: The option vests and becomes exercisable in full on July 15, 2025, subject to the reporting person's continued service with the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 16:21 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 12,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017629 · form4-06202024_080659.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,430 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on July 15, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 16:05 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | SaleCommon Stock | 3,092 | $9.97 | $30,827.24 |
DisclosureSEC source: 0001415889-24-004576 · form4-02212024_040204.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,697 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.96 to $9.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 16:19 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 114,600 | $0.00 Strike: $9.74 | $0.00 |
DisclosureSEC source: 0001415889-24-001591 · form4-01192024_090127.xml · derivative · entry 2 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,600 Underlying: Common Stock · 114,600 shares Expires 2034-01-18 F2 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments beginning on February 18, 2024, subject to the reporting person's continued service with the Issuer. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 16:19 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 25,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001591 · form4-01192024_090127.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,789 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2025, the second installment vesting on February 15, 2026, and the third installment vesting on February 15, 2027, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| August 08, 2023 Filed Aug 8, 2023 21:05 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | SaleCommon Stock | 14 | $8.93 | $125.02 |
DisclosureSEC source: 0001415889-23-011950 · form4-08082023_090805.xml · nonDerivative · entry 2 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,324 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. F3 · price: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.58 to $8.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:05 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | SaleCommon Stock | 2,790 | $9.54 | $26,616.60 |
DisclosureSEC source: 0001415889-23-011950 · form4-08082023_090805.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · CFO AND COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,338 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.38 to $9.83, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 16:33 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 126,585 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001415889-23-001581 · form4-01302023_090151.xml · derivative · entry 2 Pfanstiel Steven · CIK 0001856059 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,585 Underlying: Common Stock · 126,585 shares Expires 2033-01-26 F2 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments beginning on February 26, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 16:33 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 28,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-001581 · form4-01302023_090151.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,128 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2024, the second installment vesting on February 15, 2025, and the third installment vesting on February 15, 2026, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| May 24, 2022 Filed May 26, 2022 16:01 UTC | MARINUS PHARMACEUTICALS, INC. MRNS] · Entity 83359 | GrantCommon Stock | 7,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-065237 · tm2216988-2_4seq1.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,998 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in two equal installments, with the first installment vesting on August 4, 2023, and the second installment vesting on August 4, 2024, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| February 04, 2022 Filed Feb 7, 2022 16:13 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 74,475 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001104659-22-012794 · tm225605-11_4seq1.xml · derivative · entry 2 Pfanstiel Steven · CIK 0001856059 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,475 Underlying: Common Stock · 74,475 shares Expires 2032-02-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments beginning on March 4, 2022. Read SEC document |
| February 04, 2022 Filed Feb 7, 2022 16:13 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 16,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-012794 · tm225605-11_4seq1.xml · nonDerivative · entry 1 Pfanstiel Steven · CIK 0001856059 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,550 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on August 4, 2023, the second installment vesting on August 4, 2024, and the third installment vesting on August 4, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 21:59 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 220,000 | $0.00 Strike: $13.99 | $0.00 |
DisclosureSEC source: 0001104659-21-049910 · tm2112857-2_4seq1.xml · derivative · entry 1 Pfanstiel Steven · CIK 0001856059 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2031-04-12 F1 · derivative.exercise_date: Options to purchase shares of common stock vest 25% on 4/12/22, and the remainder in 36 equal monthly installments, commencing on 4/30/22. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.